Indivior Pharmaceuticals Inc (INDV) Smart Money Holdings (13F, Q2 2026)

INDV ranks #1860 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

INDV is a disclosed holding of Howard Marks (Oaktree Capital Management), one of the tracked superinvestors on AlphaSMO — it makes up 3.5% of that fund's own 13F portfolio.

INDV is a top-conviction position for Mangrove Partners Im, LLC — at 7.2% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in INDV belongs to BlackRock, Inc., but the position matters far more to Mangrove Partners Im, LLC, who has 7.2% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Invesco Ltd. has added to its INDV position for two straight quarters, increasing it by $65.3M to reach $75.6M today.

Madison Avenue Partners, LP has trimmed its INDV position for two straight quarters, cutting it by $107.4M while still holding $117.9M.

INDV is down 0.4% today, but institutions show net buying of $222.5M this quarter — a divergence between today's price move and the underlying institutional flow.

INDV posted net income of $355.0M over the trailing twelve months, and currently trades at a P/E of 12.9.

• Profitable — net income of $355.0M over the trailing twelve months
• Revenue grew 13.5% year over year
• Net income improved year over year, from $108.0M to $355.0M
• Operating cash flow was negative, using $27.0M in cash
• Current ratio of 0.71x — below the conventional 1.5x liquidity buffer